

JFW



PATENT
Attorney Docket No. VACCINE-07971

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of: David R. Milich *et al.*

Serial No.: 10/630,074


Group No.: 1646

Filed: 07/30/2003

Examiner:

Entitled: **Human Hepatitis B Virus Core Proteins As Vaccine
Platforms And Methods Of Use Thereof****INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>September 1</u> , 2004	By: <u></u> Cliff Cannon-Cin


Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: September 1, 2004Maha A. Hamdan

Maha A. Hamdan
Registration No. 43,655
MIDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415/904-6500



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David R. Milich *et al.*

Serial No.: 10/630,074

Group No.: 1646

Filed: 07/30/2003

Examiner:

Entitled: **Human Hepatitis B Virus Core Proteins As
Vaccine Platforms And Methods Of Use
Thereof**

**SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 9-1-04.

By: [Signature]

Cliff Cannon-Cin

Sir or Madam:

The citation listed below, copy attached, may be material to the examination of the above-identified application, and is therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make this citation of official record in this application:

- Chang *et al.*, "Phenotypic Mixing between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be *cis* Preferential," (1994) J. Virol. 5225-5231.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material

PATENT

Attorney Docket No. VACCINE-07971

to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 1, 2004

Maha A. Hamdan

Maha A. Hamdan

Registration No. 43,655

MEDLEN & CARROLL, LLP

101 Howard Street, Suite 350

San Francisco, California 94105

415/904-6500

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-07971	Serial No.: 10/630,074
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: David R. Milich <i>et al.</i>	
				Filing Date: 07/30/2003	Group Art Unit: 1646
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	1	Chang <i>et al.</i> , "Phenotypic Mixing between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be <i>cis</i> Preferential," (1994) J. Virol. 5225-5231			
Examiner:				Date Considered:	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					